13 results about "Level insulin" patented technology

The invention belongs to the technical field of food processing, and particularly relates to a product with peony peptide and ginseng peptide as main raw materials and a preparation method of the product. According to the invention, leftovers such as ginseng root hair and peony seed meal are used as raw materials, so that the production cost is greatly reduced, and the prepared product is presented in the form of a solid beverage and is convenient to carry and drink; the ginseng peptide is prepared by adopting a steam explosion and biological enzymolysis technology, the peony peptide is prepared by adopting a microbial fermentation mode, the molecular weight of the polypeptide is reduced, digestion and absorption are facilitated, meanwhile, the yield and oxidation resistance of the peptide are improved by adopting the microbial fermentation mode, the highest yield can reach 45.5%, and the highest oxidation resistance can reach 72.5%; besides, isomaltulose is also added while the bovine bone collagen peptide powder, the ginseng peptide powder and the peony peptide powder are adopted, so that the taste of the product is improved, the reconstituability of the product is improved, the fluctuation of blood sugar and insulin level is not caused after the product is taken, and the product can also be drunk by diabetics.

The present disclosure relates to a use of Lacticaseibacillus rhamnosus FMBL L23004 CNN in the preparation of a medicament for preventing or treating diabetes mellitus. The Lacticaseibacillus rhamnosus FMBL L23004 CNN was deposited with the China Center for Type Culture Collection (CCTCC) on 26 Jun. 2023 under the accession number CCTCC NO: M 20231099. The Lacticaseibacillus rhamnosus FMBL L23004 CNN strain has the effect of inhibiting the activity of α-glucosidase, α-amylase, and dipeptidyl peptidase IV. Administration of the strain can significantly lower oral glucose tolerance and insulin tolerance in Type 2 Diabetes Mellitus (T2DM) mice, reduce abnormal postprandial blood glucose fluctuations, decrease fasting blood glucose levels, lower fasting insulin levels, reduce blood lipid levels, and alleviate insulin resistance. The strain significantly improves the composition of the gut microbiome, increases the abundance and diversity of beneficial gut bacteria, and reduces the relative abundance of pathogenic bacteria.

The present invention belongs to the field of functional foods, and specifically relates to a composition for lowering glucose and stabilizing an insulin level, a preparation method therefor, and use thereof. The composition of the present invention comprises a component I and a component II. The component I is cyclodextrin and a derivative thereof, the component II is naringenin and a derivative thereof, and the mass ratio of the component I to the component II is (0.1-100):(0.01-1). After being eaten with a meal or added to food, especially high-carbohydrate food, the composition of the present invention can significantly maintain the stability of the insulin level in the body while significantly controlling the postprandial blood glucose level. Long-term use can achieve the effects of stabilizing triglyceride, low-density lipoprotein, and high-density lipoprotein levels.

The present invention provides a powdered mixture comprising a non-dairy whipped topping, an isolated protein powder, and a plant-based sweetener that does not affect blood sugar or insulin levels. Importantly, the confection can easily be made at home using only water to reconstitute the powdered ingredients and comes in a variety of flavors. The confections disclosed herein can be configured in a solid form, a powdered form, a frozen confection, or as a semisolid or frozen beverage.

The invention provides application of an allium mongolicum extract. The allium mongolicum extract is used for preparing a feed for improving metabolism-related fatty liver diseases. The allium mongolicum extract disclosed by the invention is derived from natural plant compounds, has relatively high safety, can be used for reducing blood sugar and insulin levels of serum, reducing biochemical index levels of the serum and improving fatty degeneration of the liver, and exerts a positive protection effect on metabolism-related fatty liver diseases by cooperatively regulating lipid metabolism-related genes; the method has guiding significance for subsequent further development and utilization.

Described herein are methods of treatment of metabolic syndrome using Cannabis Plant Material to reduce fasting glucose and insulin and lower the homeostasis model assessment-estimated insulin resistance (HOMA-IR) index to mitigate metabolic syndrome and associated Type II Diabetes, Coronary Heart Disease, and Stroke, pharmacological compounds for same and methods for making the pharmacological compounds.

The present application relates to the technical field of biotechnology, and discloses a plant Lactobacillus plantarum XKFY202518 and application of the plant Lactobacillus plantarum XKFY202518 in preparation of a type 2 diabetes auxiliary preparation for improving insulin resistance and regulating blood lipid, the plant Lactobacillus plantarum XKFY202518 has a preservation number of CGMCC No.34745 in China General Microbiological Culture Collection Center, and a preservation date of June 3, 2025.The plant Lactobacillus plantarum XKFY202518 separated by the present application can effectively reduce the fasting blood glucose level, insulin level, total cholesterol level, triglyceride level, low-density lipoprotein cholesterol level, alanine aminotransferase level and aspartate aminotransferase level of a diabetic mouse, and increase the high-density lipoprotein cholesterol level of the mouse serum, thereby improving the hyperglycemia and hyperlipidemia symptoms of a type 2 diabetes mouse.

The invention relates to the technical field of gestational diabetes mellitus detection, and discloses a gestational diabetes mellitus serum marker detection data analysis system. The system comprises a serum biochemical data acquisition module, a detection device is used for acquiring a serum sample of a pregnant woman, and a serum biochemical data set containing blood sugar concentration, insulin level and glycosylated hemoglobin indexes is constructed; a multi-dimensional index integration module combines a historical detection time sequence and the physiological parameter information of the current detection time period to generate an integrated data set containing time dimension correlation features; the abnormal risk analysis module processes the time dimension correlation features in the integrated data set, and calculates the risk deviation value of gestational diabetes in the current detection period; when the risk deviation value is abnormal, the risk grading module generates a plurality of candidate intervention classification schemes based on the serum biochemical data set, and outputs the intervention influence degree of each candidate scheme; and an intervention scheme generation module screens the candidate scheme with the lowest intervention influence degree and generates an optimal intervention classification scheme in the current detection time period.

A method and vectors for controlling blood glucose levels in a mammal are disclosed. In one embodiment, the method comprises the steps of: treating the hepatocyte cells of a patient with a first, second or third vector, wherein the first vector comprises a promoter enhancer, glucose inducible regulatory elements, a liver-specific promoter, a gene encoding human insulin with modified peptidase and an albumin 3′UTR and lacks an HGH intron, wherein the second vector comprises an HGH intron, glucose inducible regulatory elements, a liver-specific promoter, a gene encoding human insulin with modified peptidase site and an albumin 3′UTR and lacks a promoter enhancer, wherein the third vector comprises an HGH intron, glucose inducible regulatory elements, a liver-specific promoter, a gene encoding human insulin with modified peptidase site, an albumin 3′UTR and a promoter enhancer and observing the patient's insulin levels, wherein the patient's insulin levels are controlled.

The present invention provides a powdered mixture comprising a non-dairy whipped topping, an isolated protein powder, and a plant-based sweetener that does not affect blood sugar or insulin levels. Importantly, the confection can easily be made at home using only water to reconstitute the powdered ingredients and comes in a variety of flavors. The confections disclosed herein can be configured in a solid form, a powdered form, a frozen confection, or as a semisolid or frozen beverage.

Disclosed herein are techniques related to automatic real-time meal detection. In some embodiments, the techniques involve obtaining a plurality of glucose concentration values and a plurality of plasma insulin concentration estimations, each glucose concentration value corresponding with a respective plasma insulin concentration estimation; generating an output based on applying a meal detection model to the plurality of glucose concentration values and the plurality of plasma insulin concentration estimations; and determining, based on the output, that a glucose concentration value of the plurality of glucose concentration values corresponds to an ongoing glycemic response to a meal.

Embodiments relate to systems and methods for informing, determining, or controlling insulin dosage. The method involves generating plural disturbance profiles, each disturbance profile being a data representation based on historical patient data pertaining to a deviation from a threshold blood glucose level. The method involves receiving current patient data. The method involves applying a predictive model so that current patient data is compared to a disturbance profile and a probability analysis is used to assess the likelihood of a disturbance profile being an anticipated disturbance profile, the anticipated disturbance profile being a disturbance profile that is determined to match with the current patient data based on the probability analysis. The method involves determining an insulin dose amount based on the anticipated disturbance profile. The method involves outputting a signal representative of the insulin dose amount to a device configured for monitoring, influencing, and / or administering insulin levels in the patient.

This invention discloses a composition for the prevention or treatment of diabetes and its application, relating to the field of pharmaceutical technology. The composition is a combination of any of the following components: a mitochondrial protectant, a vanadium compound, and a hormone / pheromone. It can improve pancreatic β-cell activity and control fasting blood glucose, satiety blood glucose, glucose tolerance, and insulin levels within dietary dosage ranges.